Editas Medicine, a genome editing company, has named James Mullen as its new chairman of the board of directors, it was reported yesterday.
Mullen has more than 30 years' experience leading biotechnology and pharmaceutical organisations on a global scale. Earlier, he has served as chief executive officer of Patheon. Before joining Patheon, Mullen served as chief executive officer and president at Biogen and before this he held numerous roles at the biotech.
Katrine Bosley, president and chief executive officer of Editas Medicine, said, 'Jim is a renowned leader in the biotechnology industry with deep experience building global companies and guiding corporate strategy, and I am very pleased to welcome his as chairman of the board. Jim's extensive experience in driving excellence across R&D, commercialisation, manufacturing, business development and capital formation will be invaluable as we continue to build a genomic medicine leader and develop medicines for patients in the years to come.'
Convergent Therapeutics names new chairman of board of directors
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Cardinal Health names new independent director
Micron Biomedical names new scientific advisor to CEO
MedPharm names new executive chairman
Armonica Technologies names new director
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Jazz Pharmaceuticals names new executive vice president and chief financial officer
Ardigen names new chief commercial officer
AbbVie names new chief executive officer
AMO Pharma collaborates with Population Health Research Institute for tideglusib clinical trial